Ultra-High-Field 7T Metabolic Imaging Shows Promise for Classifying Diffuse Gliomas

Ultra-high-field magnetic resonance spectroscopic imaging at 7 Tesla can measure the metabolic fingerprints of adult-type diffuse gliomas non-invasively, and in a prospective study of fifty patients several metabolite ratios performed as well as, or slightly better than, conventional MRI markers in distinguishing the three main glioma subtypes. The findings, published in Cancer Imaging, offer preliminary evidence that 7T MRSI could support the non-invasive characterization of glioblastoma, IDH-mutant astrocytoma, and oligodendroglioma, though the authors emphasize that validation in larger cohorts is still needed.

Established clinical MR imaging offers limited accuracy for the precise classification of adult-type diffuse glioma. The research team, led by investigators including Sara Huskic and Gilbert Hangel, set out to identify robust 7T MRSI metabolic markers that distinguish glioblastoma, IDH-wildtype (GBM); astrocytoma, IDH-mutant (AST); and oligodendroglioma, IDH-mutant, 1p/19q-codeleted (ODG), and to assess how these markers compare with established radiological ones.

The study prospectively enrolled patients with suspected adult-type diffuse glioma, with final diagnoses established according to the 2021 WHO classification. Fifty patients were included: fifteen with glioblastoma, twenty-four with IDH-mutant astrocytoma, and eleven with oligodendroglioma. Each patient underwent routine 3T MRI comprising contrast-enhanced T1-weighted imaging, T2, FLAIR, and diffusion-weighted ADC mapping, alongside 7T MRSI acquired with a 3D-FID-CRT sequence. Median metabolite values within tumors were extracted from sixteen metabolite maps, and group differences and predictive performance were analyzed using non-parametric statistics and ROC-curve analysis.

The results showed subtype-specific metabolic signatures. For separating glioblastoma from IDH-mutant astrocytoma, five metabolite ratios proved discriminatory: mI/tNAA, Glu/tCr, Gln/tCr, Glx/tCr, and mI/tCr, with areas under the ROC curve between 0.78 and 0.86. Eight ratios distinguished glioblastoma from oligodendroglioma with AUCs below 0.93, a performance the authors describe as comparable to and slightly more robust than the clinical standard in this cohort.

For distinguishing IDH-mutant astrocytoma from oligodendroglioma, tCho/tNAA and GSH/tNAA were the most predictive ratios, with AUCs below 0.90.

The authors conclude that 7T MRSI enables non-invasive metabolic profiling of gliomas and shows potential for differentiating GBM, AST, and ODG, with several metabolite ratios demonstrating discriminatory performance comparable to conventional MRI markers in this cohort. They frame the work as preliminary evidence supporting 7T MRSI for glioma subtype characterization and call for further validation in larger studies.

Several limitations temper the immediate clinical implications. The cohort of fifty patients is small, particularly the eleven-patient oligodendroglioma group, and the article was released early as a peer-reviewed, accepted version that may still be edited before the final Version of Record.

Subject of Research: Using 7T magnetic resonance spectroscopic imaging metabolite ratios to non-invasively classify adult-type diffuse glioma subtypes.

Article Title: Classifying adult-type diffuse glioma using 7T magnetic resonance spectroscopic imaging

Article References: Huskic, S., Lazen, P., Roetzer-Pejrimovsky, T., Rumbak, R., Azgin, A., Koerner, L., Kiesel, B., Motyka, S., Strasser, B., Hingerl, L., Leitner, J., Hennenberg, J., Preusser, M., Berghoff, A. S., Kloss-Brandstätter, A., Rössler, K., Grabner, G., Bogner, W., Widhalm, G., & Hangel, G. (2026). Classifying adult-type diffuse glioma using 7T magnetic resonance spectroscopic imaging. Cancer Imaging. https://doi.org/10.1186/s40644-026-01124-7

Image Credits: AI Generated

DOI: 10.1186/s40644-026-01124-7

Keywords: 7T MRSI, adult-type diffuse glioma, glioblastoma, IDH-mutant astrocytoma, oligodendroglioma, metabolite ratios, magnetic resonance spectroscopic imaging, WHO 2021 classification, ROC analysis, non-invasive diagnosis, Cancer Imaging, ultra-high-field MRI